In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents

Anti-Cancer Drugs

Volumn 16, Issue 8, 2005, Pages 825-835

  To, Kenneth K W ^a   Ho, Yee Ping ^a   Au Yeung, Steve C R ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Demethylcantharidin; Human hepatocellular carcinoma; Platinum anti cancer agents; Protein phosphatase inhibition; Traditional Chinese medicine; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEMETHYLCANTHARIDIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHINESE MEDICINE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LETHAL DOSE; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED ICR; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PHOSPHOPROTEIN PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 24044527863     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000175586.31940.50     Document Type: Article

References (34)

1. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59:9-17.
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-464.
3. Rosenberg B. Platinum complexes for the treatment of cancer: why the search goes on. In: Lippert B (editor). Chemistry and Biochemistry of a Leading Anticancer Drug. New York: Wiley-VCH; 1999, pp. 1-27.
4. Ho YP, To KKW, Au-Yeung SCF, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001; 44:2065-2068.
5. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989; 26:147-162.
6. Yi SN, Wass J, Vincent P, Hand H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1992; 15:883-886.
7. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 1992; 89:11867-11870.
8. Graziano MJ, Waterhouse AL, Casida JE. Cantharidin poisoning associated with specific binding site in liver. Biochem Biophys Res Commun 1987; 149:79-85.
9. Graziano MJ, Pessah IN, Matsuzawa M, Casida JE. Partial characterization of specific cantharidin binding sites in mouse tissues. Mol Pharmacol 1988; 33:706-712.
10. Thiery JP, Blazsek I, Legras S, Marion S, Reynes M, Anjo A, et al. Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital- treated rats: characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor. Hepatology 1999; 29:1406-1417.
11. Kreamer BL, Staecker JL, Sawada N, Sattler GL, Hsia MTS, Pitot HC. Use of a low speed, iso-density Percoll® centrifugation method to increase the viability of isolated hepatocyte preparations. In Vitro Cell Dev Biol 1986; 2:201-211.
12. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
13. Ovejera AA, Houchens DP. Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents. Semin Oncol 1981; 8: 386-393.
14. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, et al. In vivo methods for screening and preclinical testing, in: Teicher B (editor). Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ: Humana Press; 1997, pp. 75-99.
15. Fodstad O. Preclinical anticancer drug evaluation in human tumor xenografts. In: Fiebig HH, Berger DP (editors). Immunodeficient Mice in Oncology. Basel: Karger; 1992, pp. 352-361.
16. Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 2000; 46:74-78.
17. Pera MF, Harder HC. Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 1977; 23:1245-1249.
18. To KKW, Wang X, Yu CW, Ho YP, Au-Yeung SCF. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. Bioorg Med Chem 2004; 12:4565-4573.
19. Murry DJ. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy 1997; 17(5 part 2):140S-145S.
20. Perry JF, Strasser SI, George J, Farrell GC, McCaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opin Pharmacother 2003; 4:2175-2185.
21. Cusnir M, Pratt YZ. Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004; 8:97-103.
22. Shouval D, Schuger L, Levij LIS, Reid LM, Neeman Z, Shafritz DA. Comparative morphology and tumourigenicity of human hepatocellular carcinoma cell lines in athymic rats and mice. Virchows Arch A Pathol Anat Histopathol 1988; 412:595-606.
23. Liu P, Menon K, Alvarez E, Lu K, Teicher BA. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 2000; 16:599-610.
24. Mellgren G, Vintermyr OK, Boe R, Doskeland SO. Hepatocyte DNA replication is abolished by inhibitors selecting protein phosphatase 2A rather that phosphatase 1. Exp Cell Res 1993; 205:293-301.
25. Alemany S, Tung HYL, Shenolikar S, Pilkis SJ, Cohen P. The protein phosphatases involved in cellular regulation. Antibody to protein phosphatase-2A as a probe of phosphatase structure and function. Eur J Biochem 1984; 145:51-56.
26. Haystead TAJ, Sim ATR, Carling D, Honnor RC, Tsukitani Y, Cohen P, et al. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 1989; 337:78-81.
27. Doskeland AP, Vintermyr OK, Flatmark T, Cotton RGH, Doskeland SO. Phenylalanine positively modulates the cAMP-dependent phosphorylation and negatively modulates the vasopressin-induced and okadaic acid-induced phosphorylation of phenylalanine 4-monooxygenase in intact rat hepatocytes. Eur J Biochem 1992; 206:161-170.
28. Ekanger R, Vintermyr OK, Houge G, Sand TE, Scott JD, Krebs EG, et al. The expression of cAMP-dependent protein kinase subunits is differentially regulated during liver regeneration. J Biol Chem 1989; 264:4374-4382.
29. 3H]-thymidine labelling patterns to determine rapid changes in the rate of onset of DNA replication. J Cell Phys 1989; 141:371-382.
30. To KKW, Ho YP, Au-Yeung SCF. Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum compounds with anticancer activity by gas chromatography. J Chromatogr A 2002; 947:319-326.
31. Nitschke R. Renal complications of cis-diamminedichloroplatinum. Ann Clin Lab Sci 1981; 11:392-396.
32. Levi J, Jacobs C, Kalman SM, McTique M, Weiner MW. Mechanism of cisplatinum nephrotoxicity: 1. Effect of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 1980; 213:545-550.
33. Foster BJ, Harding BJ, Wolpert-BeFilippes MK, Rubinstein LY, Clagett-Carr K, Leyland-Jones B. A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. Cancer Chemother Pharmacol 1990; 25:395-404.
34. Au Yeung SCF, Ho YP, Lin G, Han X, Wang X, Lu S, Jiang T. Synthesis of platinum complexes and uses thereof. US Patent 6,110,907; 2000.